EMG
CLVS

Ellington Management Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Ellington Management Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,900
Closed -$552K – 912
2017
Q2 		$552K Buy
+5,900
New +$361K 0.08% 211
2013
Q3 		– Sell
-4,500
Closed -$301K – 1011
2013
Q2 		$301K Buy
+4,500
New +$202K 0.06% 512

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ellington Management Group's CLVS Position: Q3 2017 in Review

Ellington Management Group sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 5,900 shares — an estimated $552K sold.

Ellington Management Group first reported a position in CLVS in Q2 2013 and held it in 2 quarters. The position peaked at $552K in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Ellington Management Group reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 5,900 Clovis Oncology, Inc. shares in Q3 2017, an estimated $552K.
  • Ellington Management Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 2 quarters.
  • Ellington Management Group's Clovis Oncology, Inc. position peaked at $552K in Q2 2017.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.